PF-592,379
PF-592,379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which is under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2] Development has since been discontinued.[3]
Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
Chemical and physical data | |
Formula | C13H21N3O |
Molar mass | 235.331 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- Attkins N, Betts A, Hepworth D, Heatherington AC (November 2010). "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 40 (11): 730–42. doi:10.3109/00498254.2010.514961. PMID 20836725.
- Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, Caine SB (June 2012). "Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats". Behavioural Pharmacology. 23 (3): 280–91. doi:10.1097/FBP.0b013e3283536d21. PMC 3365486. PMID 22470105.
- "Drug Profile: PF 592379". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.